Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised studyJavier Cortés, Chris Twelves, Véronique Dièras et al.|The Lancet|2011Cited by 1.1k
Phase II Study of Eribulin Mesylate, a Halichondrin B Analog, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a TaxaneLinda T. Vahdat, Joanne L. Blum, Brian Pruitt et al.|Journal of Clinical Oncology|2009Cited by 245
Phase II Study of the Halichondrin B Analog Eribulin Mesylate in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane, and CapecitabineJavier Cortés, Mary Ann Allison, Linda T. Vahdat et al.|Journal of Clinical Oncology|2010Cited by 217
Molecular Profiling of Human Mammary Gland Links Breast Cancer Risk to a p27+ Cell Population with Progenitor CharacteristicsSibgat Choudhury, Kornélia Polyák, Vanessa Almendro et al.|Cell stem cell|2013Cited by 79